John Overdeck’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-20,623
| Closed | -$3.56M | – | 5115 |
|
|
2026
Q1 | $3.56M | Sell |
20,623
-7,482
| -27% | -$1.39M | ﹤0.01% | 2293 |
|
|
2025
Q4 | $5.61M | Sell |
28,105
-39,656
| -59% | -$7.19M | 0.01% | 1612 |
|
|
2025
Q3 | $10.6M | Sell |
67,761
-25,913
| -28% | -$4.12M | 0.02% | 929 |
|
|
2025
Q2 | $14.2M | Sell |
93,674
-69,669
| -43% | -$9.29M | 0.03% | 670 |
|
|
2025
Q1 | $24.6M | Buy |
163,343
+84,482
| +107% | +$14.2M | 0.05% | 416 |
|
|
2024
Q4 | $14.6M | Buy |
78,861
+59,610
| +310% | +$11.5M | 0.03% | 601 |
|
|
2024
Q3 | $3.79M | Buy |
19,251
+15,495
| +413% | +$3.22M | 0.01% | 1235 |
|
|
2024
Q2 | $776K | Buy |
3,756
+2,556
| +213% | +$579K | ﹤0.01% | 2126 |
|
|
2024
Q1 | $325K | Sell |
1,200
-300
| -20% | -$71.6K | ﹤0.01% | 2525 |
|
|
2023
Q4 | $355K | Sell |
1,500
-6,000
| -80% | -$1.18M | ﹤0.01% | 2623 |
|
|
2023
Q3 | $1.47M | Hold |
7,500
| – | – | ﹤0.01% | 1679 |
|
|
2023
Q2 | $1.58M | Sell |
7,500
-500
| -6% | -$99.5K | ﹤0.01% | 1642 |
|
|
2023
Q1 | $1.61M | Sell |
8,000
-2,326
| -23% | -$527K | ﹤0.01% | 1542 |
|
|
2022
Q4 | $2.25M | Sell |
10,326
-114,911
| -92% | -$25.1M | 0.01% | 1270 |
|
|
2022
Q3 | $24.6M | Sell |
125,237
-160,524
| -56% | -$34.7M | 0.08% | 282 |
|
|
2022
Q2 | $61.1M | Buy |
285,761
+24,732
| +9% | +$6.04M | 0.2% | 135 |
|
|
2022
Q1 | $74.1M | Buy |
261,029
+172,737
| +196% | +$53.3M | 0.22% | 112 |
|
|
2021
Q4 | $33.3M | Buy |
88,292
+21,129
| +31% | +$8.21M | 0.07% | 321 |
|
|
2021
Q3 | $27.7M | Buy |
+67,163
| New | +$27.9M | 0.06% | 342 |
|
|
2021
Q2 | – | Sell |
-1,500
| Closed | -$435K | – | 4117 |
|
|
2021
Q1 | $435K | Buy |
+1,500
| New | +$417K | ﹤0.01% | 3057 |
|
|
2020
Q3 | – | Sell |
-59,129
| Closed | -$10.3M | – | 3164 |
|
|
2020
Q2 | $10.3M | Buy |
59,129
+26,902
| +83% | +$4.29M | 0.05% | 382 |
|
|
2020
Q1 | $4.07M | Sell |
32,227
-23,155
| -42% | -$3.47M | 0.03% | 597 |
|
|
2019
Q4 | $8.46M | Buy |
55,382
+37,374
| +208% | +$5.17M | 0.03% | 695 |
|
|
2019
Q3 | $2.38M | Buy |
+18,008
| New | +$2.41M | 0.01% | 1288 |
|
|
2019
Q2 | – | Sell |
-12,992
| Closed | -$1.89M | – | 3377 |
|
|
2019
Q1 | $1.89M | Sell |
12,992
-3,545
| -21% | -$466K | 0.01% | 1456 |
|
|
2018
Q4 | $1.87M | Buy |
+16,537
| New | +$2.07M | 0.01% | 1273 |
|
|
2017
Q4 | – | Sell |
-51,564
| Closed | -$5.57M | – | 3138 |
|
|
2017
Q3 | $5.57M | Sell |
51,564
-123,385
| -71% | -$12.7M | 0.02% | 756 |
|
|
2017
Q2 | $17.7M | Sell |
174,949
-121,094
| -41% | -$11.1M | 0.06% | 366 |
|
|
2017
Q1 | $26.6M | Buy |
296,043
+32,600
| +12% | +$2.77M | 0.09% | 300 |
|
|
2016
Q4 | $20.1M | Buy |
263,443
+119,546
| +83% | +$9.08M | 0.08% | 309 |
|
|
2016
Q3 | $12M | Buy |
143,897
+10,892
| +8% | +$913K | 0.04% | 471 |
|
|
2016
Q2 | $11M | Sell |
133,005
-69,708
| -34% | -$5.74M | 0.05% | 451 |
|
|
2016
Q1 | $15.4M | Buy |
202,713
+137,825
| +212% | +$10.2M | 0.07% | 325 |
|
|
2015
Q4 | $5.22M | Buy |
64,888
+52,339
| +417% | +$3.77M | 0.03% | 653 |
|
|
2015
Q3 | $797K | Buy |
12,549
+4,588
| +58% | +$329K | ﹤0.01% | 1318 |
|
|
2015
Q2 | $560K | Sell |
7,961
-143,228
| -95% | -$10.6M | ﹤0.01% | 2045 |
|
|
2015
Q1 | $12M | Buy |
151,189
+131,934
| +685% | +$9.73M | 0.06% | 413 |
|
|
2014
Q4 | $1.23M | Sell |
19,255
-61,278
| -76% | -$3.84M | 0.01% | 1280 |
|
|
2014
Q3 | $4.81M | Sell |
80,533
-188,274
| -70% | -$10.8M | 0.02% | 629 |
|
|
2014
Q2 | $14.4M | Sell |
268,807
-80,864
| -23% | -$4.44M | 0.06% | 399 |
|
|
2014
Q1 | $21.1M | Buy |
349,671
+167,652
| +92% | +$9.77M | 0.11% | 253 |
|
|
2013
Q4 | $9.65M | Buy |
182,019
+35,499
| +24% | +$1.78M | 0.05% | 441 |
|
|
2013
Q3 | $6.78M | Sell |
146,520
-13,739
| -9% | -$630K | 0.04% | 440 |
|
|
2013
Q2 | $6.58M | Buy |
+160,259
| New | +$6.87M | 0.05% | 448 |
|
Other funds holding CRL
AI
John Overdeck's CRL Position: Q2 2026 in Review
John Overdeck sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 20,623 shares — an estimated $3.56M sold.
John Overdeck first reported a position in CRL in Q2 2013 and held it in 44 quarters. The position peaked at $74.1M in Q1 2022. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- John Overdeck reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
- John Overdeck sold 20,623 Charles River Laboratories shares in Q2 2026, an estimated $3.56M.
- John Overdeck first reported a position in Charles River Laboratories in Q2 2013 and held it in 44 quarters.
- John Overdeck's Charles River Laboratories position peaked at $74.1M in Q1 2022.
- 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.